Company & Sponsor Intelligence
Peking University Third Hospital
Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.
Request enterprise analysis →Indexed trials1
Recruiting1
Completed0
Countries1
Therapeutic footprint
unclassified
Indexed studies
NCT07423013Evaluating the Efficacy and Safety of Teprotumumab N01 in Patients With Thyroid Eye Disease.
unclassified · ChinaNA
unclassified · ChinaNA
Intelligence layer updated: 2026-06-10 02:57:56.223123+00:00
Enterprise intelligence
Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.
Request comparative intelligence →